Headache News and Research

Latest Headache News and Research

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Vanda Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration has approved HETLIOZ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is the first FDA approved medication for Non-24.

31 Jan 2014

Loyola University neuropsychologist find little evidence that chronic traumatic encephalopathy actually exists

The media have widely reported that a debilitating neurological condition called chronic traumatic encephalopathy is a well-established disease in retired athletes who played football and other contact sports.

28 Jan 2014

S. pneumoniae predicts acute sinusitis microbial response

Research from the USA shows that confirmed nasopharyngeal colonization with Streptococcus pneumoniae independently predicts a rapid response to antimicrobial therapy in children with acute sinusitis.

27 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Novo Nordisk, a world leader in diabetes care, today announced the launch of the insulin delivery device NovoPen Echo in the United States. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that records the dose and time passed since the last injection.

From Novo Nordisk 21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

21 Jan 2014

Middle-school girls often continue playing soccer with concussion symptoms

Concussions are common among middle-school girls who play soccer, and most continue to play with symptoms, according to a study by John W. O' Kane, M.D., of the University of Washington Sports Medicine Clinic, Seattle, and colleagues.

20 Jan 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi (sofosbuvir) 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic hepatitis C infection in adults, in combination with other antiviral agents (ribavirin and pegylated interferon alpha (peg-IFN)).

18 Jan 2014

New drug combination proves effective in treatment of hepatitis C

Efforts to cure hepatitis C, the liver-damaging infectious disease that has for years killed more Americans than HIV/AIDS, are about to get simpler and more effective, according to new research at Johns Hopkins and elsewhere.

16 Jan 2014

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults.

15 Jan 2014

Study shows that high-blood pressure medicine may also prevent migraines

Candesartan is just as effective as more the commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).

13 Jan 2014

Study questions widely used method of diagnosing acute mountain sickness

A study led by University of British Columbia scientists calls into question a widely used method of diagnosing acute mountain sickness.

9 Jan 2014

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations.

9 Jan 2014

Merck announces FDA approval of ISENTRESS for oral suspension

Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration recently approved ISENTRESS for oral suspension, a new pediatric formulation of Merck's integrase inhibitor. With this approval, ISENTRESS is now indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients four weeks of age and older.

9 Jan 2014

Quick tips to avoid carbon monoxide poisoning

Temperatures in the next few days are predicted to be the coldest of the winter so far, and people using space heaters to get some extra warmth into their living and working spaces need to be aware of a potential "silent killer" inside their homes and offices — carbon monoxide (CO).

8 Jan 2014

New study finds that Americans had more health concerns during the recession

We ring in the New Year with hopes of being healthy, wealthy, and wise. A new study led by San Diego State University School of Public Health research professor John W. Ayers suggests that from a public health standpoint, health and wealth may be connected.

8 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

Amneal Pharmaceuticals LLC today announced the launch of generic Esomeprazole strontium delayed-release capsules 49.3 mg. This new esomeprazole therapy is the generic equivalent of the recently launched brand Esomeprazole strontium. It contains the same active moiety (esomeprazole) in a different salt form as found in the leading PPI brand Nexium (esomeprazole magnesium) and presents a potentially more affordable treatment option for GERD in adult patients.

6 Jan 2014

Headache News and Research

Latest Headache News and Research

Vanda Pharmaceuticals announces FDA approval of HETLIOZ for Non-24 treatment

Loyola University neuropsychologist find little evidence that chronic traumatic encephalopathy actually exists

S. pneumoniae predicts acute sinusitis microbial response

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Novo Nordisk launches insulin delivery device NovoPen Echo in the U.S.

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

European Commission approves ViiV Healthcare's Tivicay for treatment of HIV infected adults

Middle-school girls often continue playing soccer with concussion symptoms

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

New drug combination proves effective in treatment of hepatitis C

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Study shows that high-blood pressure medicine may also prevent migraines

Study questions widely used method of diagnosing acute mountain sickness

GSK receives FDA approval for combination of Mekinist with Tafinlar for treatment of melanoma

Merck announces FDA approval of ISENTRESS for oral suspension

Quick tips to avoid carbon monoxide poisoning

New study finds that Americans had more health concerns during the recession

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Amneal launches generic Esomeprazole strontium delayed-release capsules 49.3 mg

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in